BPC-157 Peptide 10mg – Body Protection Compound

Chemical diagram for BPC-157 by User:Innerstream – Own work, Public Domain, https://commons.wikimedia.org/w/index.php?curid=154789519

KEY SPECIFICATIONS

PRODUCT OVERVIEW

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of a naturally occurring gastric protective protein. The 15-amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) demonstrates remarkable stability in gastric juice conditions and has been extensively investigated in regenerative research models for over 30 years. A comprehensive 2024 review of 36 studies (1993-2024) confirms BPC-157 promotes healing through growth factor upregulation, VEGF/VEGFR2 expression modulation, and NO system regulation. The peptide activates the FAK-paxillin pathway essential for cell migration, while influencing EGR-1 and growth hormone receptor expression. Research demonstrates effects across wound healing, tendon regeneration, gastroprotection, and angiogenesis models. BIONIX supplies BPC-157 with ≥99% purity for tissue repair research.

MECHANISM OF ACTION

BPC-157’s mechanism involves multiple interconnected signaling systems regulating tissue homeostasis and repair through NO modulation, angiogenesis promotion, and cell migration enhancement.

NO System Modulation:

BPC-157 provides counter-regulatory mechanism—upregulating NO when deficient, moderating when excessive—maintaining vascular homeostasis in damaged tissue models.

VEGF/Angiogenesis Pathway:

BPC-157 stimulates VEGFR2, Akt-eNOS axis activation, and sustained NO synthesis, promoting new blood vessel formation. Effects persist for weeks despite short half-life (<30 minutes), suggesting self-sustaining gene expression cascades (Akt1, VEGFR2, eNOS).

FAK-Paxillin Cell Migration Pathway:

Chang et al. (2011) demonstrated BPC-157 stimulates fibroblast and tenocyte migration through FAK-Paxillin activation.

Structural Stability Features:

BPC-157’s stability in gastric juice (pH 1-2) is exceptional among bioactive peptides—attributed to compact structure and pepsin resistance.

Proposed Mechanism Pathway:

BPC-157 → NO System Modulation → Vascular Homeostasis / 
VEGF/VEGFR2 Upregulation → Akt-eNOS Activation → Angiogenesis / 
FAK-Paxillin Activation → Cell Migration (40% increase) / 
EGR-1 Upregulation → Growth Factor Sensitivity → Tissue Regeneration

Comparative Profile:

RESEARCH APPLICATIONS

• Wound Healing Models: Extensively studied across all three healing phases. Inflammation phase: cytokine modulation, reduced excessive inflammation. Proliferation phase: enhanced fibroblast migration and proliferation (40% increase per Chang et al.). Remodeling phase: improved collagen organization and tissue strength. Endpoints: wound closure rate (planimetry, ImageJ), granulation tissue (histological scoring), collagen organization (Picrosirius red), re-epithelialization (H&E), tensile strength (mechanical testing).

• Tendon and Ligament Research: Major focus due to limited vascularization in these tissues. Achilles tendon transection models: biomechanical strength assessment, collagen fiber alignment, VEGF expression quantification, histological healing scores. Chang et al. (2011) demonstrated enhanced cell survival, migration, and outgrowth in vitro and in vivo. BPC-157 addresses the challenge of hypovascular tissue repair through angiogenesis promotion.

• Gastroprotection Research: Origin from gastric protective protein makes GI research particularly relevant. Epithelial cell protection from NSAIDs and ethanol, mucosal barrier integrity maintenance, anastomosis and fistula healing models (colo-cutaneous, recto-vaginal), ulcer healing mechanisms. Research suggests accelerated healing at tissue junctions through simultaneous angiogenesis promotion and extracellular matrix stabilization.

• Angiogenesis Studies: Angiogenic potential investigated through multiple assays: HUVEC tube formation (network complexity), endothelial migration (cells/field), aortic ring sprouting (sprout length/number), VEGF/VEGFR2 expression (qPCR, Western blot), CAM assay (vessel density). Mechanism investigation focuses on Akt-eNOS axis activation and sustained NO synthesis for neovascularization.

• Neuroprotection Research: Emerging gut-brain axis investigations: pro-inflammatory cytokine reduction in hippocampus, neuronal integrity preservation after trauma, dopaminergic and serotonergic system interactions, behavioral studies in rodent models. Neuroprotective effects examined in Parkinson’s-like, Alzheimer’s-like, and neurotoxic exposure models.

• Inflammation and Cytokine Modulation: ERK1/2 pathway activation, reduction of inflammatory cytokines (TNF-α, IL-6), AKT phosphorylation enhancement, KRAS expression modulation. BPC-157’s counter-regulatory NO modulation provides anti-inflammatory effects without complete immunosuppression.

ANALYTICAL VERIFICATION

BIONIX BPC-157 undergoes comprehensive analytical characterization:

• HPLC Analysis: Gradient separation confirms ≥99% purity; separates pentadecapeptide from impurities, deletion sequences, and synthesis byproducts • Mass Spectrometry: Exact molecular weight confirmation (1,419.53 g/mol) and Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val sequence verification • Amino Acid Analysis: Composition quantification • Structural Confirmation: Triple proline integrity verification • Endotoxin Testing: LAL assay for cell culture applications

Physical Characteristics:

DEVELOPMENT STATUS

• Origin: Derived from naturally occurring gastric protective protein; synthetic pentadecapeptide • Research History: 30+ years of investigation; 36 studies reviewed (1993-2024) • Mechanism: NO system modulation, VEGF/angiogenesis, FAK-paxillin migration pathway • Clinical Status: Not FDA or EMA approved; research compound only • Recent Evidence: 2024 comprehensive review confirming growth factor upregulation; no major adverse effects reported in preclinical models • Key Studies: Chang et al. (2011) tendon healing; Seiwerth et al. (2018) angiogenic growth factors; Sikiric et al. (2019) musculoskeletal healing • WADA Status: Research compound (verify current prohibited list)

BIONIX BPC-157 is supplied exclusively for laboratory research purposes—not for therapeutic use, human administration, veterinary, or clinical applications.

FREQUENTLY ENCOUNTERED INQUIRIES

What is BPC-157 and how does it work?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from gastric protective protein with sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Mechanism involves NO system modulation (homeostatic regulation—upregulating when deficient, moderating when excessive), VEGF/VEGFR2 upregulation for angiogenesis, FAK-paxillin pathway activation for cell migration (40% increase per Chang et al.), and EGR-1 transcription factor upregulation for growth factor sensitivity. Triple proline structure provides exceptional stability.

What is the difference between BPC-157 and TB-500?

BPC-157 (15 amino acids) operates at the signaling/transcriptional level through NO/VEGF pathways, FAK-paxillin activation, and angiogenesis promotion—derived from gastric juice with extreme pH stability. TB-500 (7 amino acids) operates at the structural/mechanical level through G-actin sequestration and cytoskeletal dynamics—derived from Thymosin Beta-4 with N-acetylation stability. They represent complementary mechanisms often studied in combination for synergistic tissue repair effects.

Is BPC-157 water soluble?

Affirmative. BPC-157 is a polar peptide with excellent water solubility due to acidic residues (Glu, Asp-Asp). Reconstitutes easily in bacteriostatic water or sterile saline—no organic solvents (DMSO) required. This simplifies cell culture applications and eliminates solvent-related confounding factors. Triple proline and glycine termini provide conformational flexibility enhancing solubility.

What research models is BPC-157 used in?

Primary applications: wound healing (closure kinetics, collagen organization, tensile strength), tendon and ligament regeneration (Achilles transection, biomechanical testing), gastroprotection (NSAID protection, mucosal barrier, fistula healing), angiogenesis (HUVEC tube formation, VEGF expression, CAM assays), neuroprotection (gut-brain axis, neuroinflammatory reduction), and inflammation studies (cytokine modulation, ERK1/2 pathway). All applications restricted to controlled laboratory environments.

How stable is BPC-157?

Exceptionally stable due to triple proline sequence (Pro-Pro-Pro) providing structural rigidity and protease resistance. Maintains integrity in gastric juice (pH 1-2) and extreme pH conditions. Lyophilized at -20°C: stable 24+ months. Room temperature: stable up to 90 days. Post-reconstitution: 2-4 weeks at 2-8°C, 1-3 months at -20°C (aliquoted). No disulfide bonds simplify handling. This stability profile is unique among bioactive peptides.

Is BPC-157 approved for clinical use?

Negative. BPC-157 is a research compound derived from gastric protective protein, not FDA or EMA approved for therapeutic indications. 2024 review of 36 studies (1993-2024) confirms extensive preclinical research but no approved clinical applications. It is investigated exclusively in in vitro and animal models for understanding tissue repair, angiogenesis, and gastroprotective mechanisms. BIONIX supplies research-grade material for laboratory use only—not for human therapeutic application.

REFERENCES

• PMID: 29877745 — BPC 157 and standard angiogenic growth factors; GI tract healing (Curr Pharm Des, 2018)
• PMID: 30915550 — BPC 157 role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res, 2019)
• PMID: 31405021 — Systematic review into efficacy of BPC 157 as healing agent (J Clin Med, 2019)
• PMID: 21030672 — BPC 157 promoting effect on tendon healing; cell survival and migration (J Appl Physiol, 2011)
• PMID: 34380875 — BPC 157 and the central nervous system; neuroprotective mechanisms (Neural Regen Res, 2022)
• PMC, 2024 — Emerging use of BPC-157 in orthopaedic sports medicine (36 studies review, 1993-2024)